Acusphere has submitted a New Drug Application (NDA) to the FDA for approval to market Imagify (Perflubutane Polymer Microspheres for Injectable Suspension), an ultrasound imaging agent for the detection of coronary artery disease, which could prove as accurate as nuclear stress testing.

ProHance is a macrocyclic, nonionic, gadolinium-based magnetic resonance imaging (MRI) contrast agent designed for use in MRI in adults and children over two years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. ProHance is also indicated for use in MRI in adults to visualize lesions in the head and neck.

IsoRay Medical Inc.’s Proxcelan is a seed used in low dose radiation (LDR) permanent brachytherapy for prostate cancer ...